Change your perspective
HIPRABOVIS PNEUMOS
There is a broader vision of Bovine Respiratory Disease
Bovine Respiratory Desease (BRD)
Cause of losses on beef cattle farms
BRD not only represents 70% of illnesses on a beef cattle farm, it also leads to, by far, the highest health costs.
| Reduction of ADG |
14,15€ |
Including loss of daily weight gain due to clinical and sub-clinical respiratory disease. |
| Mortality |
12,99€ |
For a mortality rate of 3.1% at an average age of 4 months (including purchase price, consumption of feed and water, loss of interest, and facilities and labour costs). |
| Premature slaughter of chronically ill stock |
14,39€ |
For an incidence of 4% and slaughter at an average age of 6 months (including the factors listed above, but subtracting earnings for slaughter). |
| Veterinary expenses |
7,57€ |
For an average of 2.1 treatments per calf and 10 calves treated per consultation (including the cost of the treatment and the cost of the consultations). |
| Preventive measures (vaccination) |
12,26€ |
Includes a standard vaccination program vaccine. |
| Economic impact of BRD per calf |
61,36€ |
Source: Dr. Eduardo Yus, Unit of Epidermiology and Animal Health, Faculty of Veterinary Medicine, University of Santiago de Compostela. Spain |
Causative elements: the bacterial factor is the key
BRD is a multiaethiological condition.
The bacterial factor is the real cause that is responsible for the most serious effects of BRD.
Mannheimia haemolytica and Histophilus somni are the most important bacteria involved in BRD.
Protecting calves against these two bacteria makes it possible to limit pharmaceutical expenses.
In the U.S.A. and Canada calves are already protected against M. haemolytica and H. somni.
| |
Mannheimia haemolytica |
Histophilus somni |
| Prevalence in Spain: (1): |
24% |
43% |
| Method of action: |
the leukotoxin destroys macrophages and neutrophils, causing inflammation of the lung tissue. |
causes vasculitis and thrombosis of a capillary nature, leading to necrosis in the affected areas. |
| Pathogenic synergy with: |
IBR (2) |
BRSV (3) |
| Conclusion: |
the most recognized case |
under-diagnosed |
(1) Data obtained from Hipra’s Diagnos laboratory: 43% of samples of calves’ lungs affected by BRD received in 2006 were found positive by PCR for H. somni.
(2) Bovine leucocytes infected by the IBR virus are more sensitive to the leukotoxin of Mannheimia haemolytica. Extract from: Czuprynski CJ, Leite F, Kuckleburg C, Schultz R, Inzana T, Behling-Kelly E, Corbeil L. “Complexities of the pathogenesis of Mannheimia haemolytica and Haemophilus somnus infections: challenges and potential opportunities for prevention”. Anim. Health Res. Rev. 2004 Dec; 5(2), pp. 277-282.
(3) Prior infection by bovine respiratory syncytial virus (BRSV) increases the severity of infection by Histophilus somni. Extract from: Corbeil L, Arnold K, Kimball R, Berghaus L, Gershwin L. “Specificity of IgG and IgE antibody responses to Haemophilus somnus infection of calves”. Vet: Immunology and Immunopathology. Vol 113, Issues 1-2 15 September 2006, pp. 191-199.
Hiprabovis Pneumos: a new perspective on BRD
Protection that really is more complete:
Its composition includes the leukotoxoid of both Mannheimia haemolytica A1 and Histophilus somni.
Double-action adjuvant:
Its special formula provides a greater immunogenic effect while at the same time reducing local reactions at the inoculation point.
Dealing with the bacterial component through a campaign of vaccination makes it possible to reduce a high percentage of respiratory pathology in the young stock.
Clinical tests: evidence of the product’s effectiveness
Field test
Beef cattle farm with 130 Friesian calves in Spain with BRD symptoms and intensive stock-rearing conditions. Control Batch (66 head) vaccinated with a viral vaccine (4 antigens). Hiprabovis Pneumos Batch (64 head) vaccinated with viral vaccine (4 antigens) and Hiprabovis Pneumos.
| |
CONTROL |
HIPRABOVIS PNEUMOS |
| ANIMALS WITH SYMPTOMS |
44% |
20% |
| ANTIMICROBIALS (*) |
l114 |
26 |
| LUNG DAMAGE (**) |
44% |
20% |
| MORTALITY |
3% |
0% |
(*) No. of treatments with i.m. injection of anti-microbials for animals with clinical symptoms of BRD.
(**) Average percentage of lung tissue affected.
Data taken from "Field trial EC-HBS-LS-1001" (awaiting publication)
Challenge test
Experimental infection of 3-month-old Friesian calves with Histophilus somni (strain: C/96/14765).
Data taken from PE-1099-CB-080
HIPRABOVIS PNEUMOS
gives protection against
Mannheimia haemolytica
and Histophilus somni, for the
first time ever in Europe. |
 |
HIPRABOVIS PNEUMOS. Emulsion for injection.
Qualitative and quantitative composition: Active substances: Mannheimia haemolytica
Biotype A serotype A1, inactivated cell free suspension containing leukotoxoid
ELISA > 2.8 (*)/dose. Inactivated Histophilus somni Bailie strain MAT > 3.3
(**)/dose. (*) A minimum of 80 % of vaccinated rabbits show ELISA value of > 2.0;
the mean ELISA is >2.8. (**). A minimum of (80 % of vaccinated rabbits show
a log2 MAT value of • 3.0; the mean log2 MAT >3.3. Adjuvant: Liquid paraffin
18.2 mg/dose. Excipients: Thiomersal 0.2 mg/dose. Target species: Species: cattle.
Sub-category: calves. Age: from 2 months of age. Indications for use, specifying
the target species: Cattle: To reduce the clinical signs and lung lesions caused
by Mannheimia haemolytica serotype A1 and Histophilus somni in calves from 2
months of age. Contraindications: Do not vaccinate unhealthy animals. .Amounts
to be administered and administration route: Cattle: 2 ml / animal. Recommended
vaccination scheme: Administer one dose per calf, at 2 months of age. This 2
ml dose should be repeated after 21 days. Vaccinate calves by subcutaneous injection
in the prescapular area. It is preferable to administer the second dose on alternate
sides. The vaccine should be allowed to warm to a temperature of between 15 -
20C before administration. Shake before use. Avoid the introduction of contamination
during use. Use only sterile needles and syringes for administration. Withdrawal
period: Zero days.Immunological properties: To stimulate active immunity against
Mannheimia haemolytica A1 and Histophilus somni. ATCvet code: QI02AB. Special
precautions for storage Store and transport refrigerated (2 C – 8 C). Do not
freeze. Protect from light. Nature and composition of immediate packaging. The
container consists of 20 ml (10 doses). Type I colourless glass vials (Ph. Eur.)
and 100 ml (50 doses). Type II colourless glass vials (Ph. Eur.), Type I rubber
stoppers (Ph. Eur.) and aluminium caps. Package sizes: Cardboard box with one
glass vial of 10 doses with a rubber stopper and aluminium cap. Cardboard box
with one glass bottle of 50 doses with a rubber stopper and aluminium cap. Marketing
authorisation numbers: Spain: 1746 ESP; Ireland: 10846/5/1; Portugal: A.I.M.
nº R773/07 DGV; Hungary: 2137/1/07; France: 679889 0; United Kingdom: Vm 17533/4005;
Czech Republic: 97/012/07-C; Slovak Republic: 97/011/07-S; Austria: 8-20292;
Germany: PEI.V.03470.01.1; Poland: 1745/07; Belgium: 8501 IE 8 F17; Denmark:
39920; Netherland: REG NL 10460. LABORATORIOS HIPRA, S.A. Avda. La Selva, 135.
17170- AMER (Girona) SPAIN.
